Baker & McKenzie LLP
12/02/2024 | Press release | Distributed by Public on 12/02/2024 03:39
Baker McKenzie Advises ATB Therapeutics on EUR 54 million Series A Financing
Baker McKenzie has advised ATB Therapeutics SA, a Belgian next-generation antibody company, on the successful closing of a EUR 54 million Series A financing. With this financing, ATB Therapeutics will advance the development of oncology and immunology drug candidates based on its patented ATBioFarm platform. The financing was led by EQT Life Sciences, alongside the wider syndicate of investors including, among other, V-Bio Ventures, the Belgian Wealth Sovereign Fund SFPIM, VIVES Partners, Wallonie Entreprendre and Sambrinvest.
"Thanks to our team of specialized corporate/M&A and life sciences lawyers, we were able to contribute on the legal side to the success of this Series A financing round of ATB Therapeutics. This will further expand the potential of the ATBioFarm platform and make transformative therapies available to patients worldwide", commented Younes Sebbarh, leading the Baker McKenzie team.
Founded in 2018, ATB Therapeutics is a biotechnology company based in Marche-en-Famenne, Belgium, specializing in the discovery and development of novel antibody therapies. Utilizing a proprietary technology platform based on plant-based molecular farming, ATB Therapeutics aims to deliver targeted solutions for oncology and autoimmune diseases through innovative next-generation antibody therapies.
Baker McKenzie's Corporate Finance and Life Sciences regularly advise pharma and biotech companies, as well as financial and strategic investors on cross border and transformational transactions in the life sciences field. Most recently, Baker McKenzie advised, inter alia, AgomAb Therapeutics on its USD 100 million Series C and USD 89 million Series D financing, Numab Therapeutics in a CHF 100 million cross-over financing, Denmark-based Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie, Ariceum Therapeutics on the acquisition of UK based biotechnology company Theragnostics Ltd., on the extension of Ariceum Therapeutics' Series A financing to EUR 47.75 million, Seamless Therapeutics on a USD 12.5 million financing and in-licensing from TU Dresden; Allecra Therapeutics on an exclusive licence and supply agreement with ADVANZ PHARMA, MODAG on a strategic collaboration with Teva; Chord Therapeutics in its sale to Merck KGaA and EQT Life Sciences (formerly LSP) as lead investor in a EUR 20 million Series A equity financing of Innovative Molecules.
Legal advisor to ATB Therapeutics:
Baker McKenzie
Younes Sebbarh (senior associate, Brussels, lead lawyer), Berthold Hummel (partner, Munich), Roel Meers (partner, Brussels), Tine Torfs (associate, Brussels), Jean de Limburg Stirum (associate, Brussels), Brian Gielen (associate), Elvin Lawson (associate, Brussels), Emilien Lerouge (associate, Brussels), Veerle Lerut (of counsel, Brussels)
"Thanks to our team of specialized corporate/M&A and life sciences lawyers, we were able to contribute on the legal side to the success of this Series A financing round of ATB Therapeutics. This will further expand the potential of the ATBioFarm platform and make transformative therapies available to patients worldwide", commented Younes Sebbarh, leading the Baker McKenzie team.
Founded in 2018, ATB Therapeutics is a biotechnology company based in Marche-en-Famenne, Belgium, specializing in the discovery and development of novel antibody therapies. Utilizing a proprietary technology platform based on plant-based molecular farming, ATB Therapeutics aims to deliver targeted solutions for oncology and autoimmune diseases through innovative next-generation antibody therapies.
Baker McKenzie's Corporate Finance and Life Sciences regularly advise pharma and biotech companies, as well as financial and strategic investors on cross border and transformational transactions in the life sciences field. Most recently, Baker McKenzie advised, inter alia, AgomAb Therapeutics on its USD 100 million Series C and USD 89 million Series D financing, Numab Therapeutics in a CHF 100 million cross-over financing, Denmark-based Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie, Ariceum Therapeutics on the acquisition of UK based biotechnology company Theragnostics Ltd., on the extension of Ariceum Therapeutics' Series A financing to EUR 47.75 million, Seamless Therapeutics on a USD 12.5 million financing and in-licensing from TU Dresden; Allecra Therapeutics on an exclusive licence and supply agreement with ADVANZ PHARMA, MODAG on a strategic collaboration with Teva; Chord Therapeutics in its sale to Merck KGaA and EQT Life Sciences (formerly LSP) as lead investor in a EUR 20 million Series A equity financing of Innovative Molecules.
Legal advisor to ATB Therapeutics:
Baker McKenzie
Younes Sebbarh (senior associate, Brussels, lead lawyer), Berthold Hummel (partner, Munich), Roel Meers (partner, Brussels), Tine Torfs (associate, Brussels), Jean de Limburg Stirum (associate, Brussels), Brian Gielen (associate), Elvin Lawson (associate, Brussels), Emilien Lerouge (associate, Brussels), Veerle Lerut (of counsel, Brussels)